Li Jixi, Liu Kang, Zhang Tingting, Yang Zhendong, Wang Rensheng, Chen Gang, Kang Min
Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi, P. R. China.
Guangxi Tumor Radiation Therapy Clinical Medical Research Center Nanning 530021, Guangxi, P. R. China.
Am J Transl Res. 2018 Aug 15;10(8):2246-2263. eCollection 2018.
HNSCC is the sixth most common cancer worldwide and is characterized as an aggressive, malignant tumor. MiR-34a-5p (miR-34a) expression has been strongly linked to HNSCC development. However, the exact target gene of miRNA-34a-as well as its biological and mechanistic pathways-are unclear. It is critical that the clinical value of HNSCC receive further study. We conducted a continuous variable, meta-analysis from data found in the cancer literature as well as that provided by the Cancer Genome Atlas (TCGA) to estimate miR-34a expression in HNSCC. Next, TCGA database, microarray, and MiRWalk were all used to predict the target gene of miR-34a in HNSCC. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to explore the underlying molecular mechanism of miR-34a in HNSCC. Finally, we used Spearman's analysis and survival curves to identify the roles of related target genes involved in significant pathways during the development of HNSCC. Expression levels of miR-34a in HNSCC were significant lower than those in normal tissues (<0.05) and summary receiver operating characteristic (sROC) was 0.72. The collective results obtained from KEGG and GO indicated that miR-34a may be involved in the development of HNSCC via known cancer pathways, including the p53 and/or PI3K-Akt signalling pathways. Our results suggested miR-34a has potential use as a novel, non-invasive and highly sensitive biomarker for diagnostic in HNSCC. Finally, it likely plays an essential role in the deterioration and ultimate tumorigenesis of HNSCC through determined cancer pathways.
头颈部鳞状细胞癌（HNSCC）是全球第六大常见癌症，其特征为侵袭性恶性肿瘤。MiR - 34a - 5p（miR - 34a）的表达与HNSCC的发展密切相关。然而，miRNA - 34a的确切靶基因及其生物学和机制途径尚不清楚。对HNSCC的临床价值进行进一步研究至关重要。我们对癌症文献以及癌症基因组图谱（TCGA）提供的数据进行了连续变量的荟萃分析，以估计HNSCC中miR - 34a的表达。接下来，使用TCGA数据库、微阵列和MiRWalk来预测HNSCC中miR - 34a的靶基因。然后，利用基因本体（GO）和京都基因与基因组百科全书（KEGG）富集分析来探索miR - 34a在HNSCC中的潜在分子机制。最后，我们使用Spearman分析和生存曲线来确定在HNSCC发展过程中参与重要途径的相关靶基因的作用。HNSCC中miR - 34a的表达水平显著低于正常组织（<0.05），汇总受试者工作特征（sROC）为0.72。KEGG和GO的综合结果表明，miR - 34a可能通过已知的癌症途径参与HNSCC的发展，包括p53和/或PI3K - Akt信号通路。我们的结果表明，miR - 34a有潜力作为一种新型、非侵入性且高度敏感的生物标志物用于HNSCC的诊断。最后，它可能通过确定的癌症途径在HNSCC的恶化和最终肿瘤发生中起重要作用。
